Crinetics - Developing Therapies For Rare Endocrine Diseases

We Are Crinetics

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Read the Latest

November 18, 2021

Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Crinetics Pharmaceuticals ($CRNX) announced today that company management will participate in a fireside chat and one-on-one investor meetings at the Annual Evercore ISI HealthCONx Conference.

November 8, 2021

Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

Crinetics Pharmaceuticals ($CRNX) announced today that new data from ACROBAT Advance, the ongoing open label extension (OLE) trial of paltusotine in patients with acromegaly, will be featured in a poster presentation at the annual Society for Endocrinology BES congress in Edinburgh, Scotland.

Pipeline

We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:

Acromegaly
Neuroendocrine tumors (NETs)
Congenital hyperinsulinism (congenital HI)
Syndromic hyperinsulinism (syndromic HI)
Cushing’s disease
Congenital adrenal hyperplasia (CAH)

Our investigational drug for acromegaly is entering Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
See the science >